Evidence map›Paper›PMID 35426944›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2022

Benchmark Dose Modeling Approaches for Volatile Organic Chemicals Using a Novel Air-Liquid Interface In Vitro Exposure System.

Adam M Speen, Jessica R Murray, Quentin Todd Krantz, David Davies, Paul Evansky, Joshua A Harrill, Logan J Everett, Joseph L Bundy, Lisa A Dailey, Jazzlyn Hill and 5 more

Open access · greenAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Frontiers in toxicology · 2026
    Article
  3. Article
  4. Article
  5. New approach methodologies (NAMs) for theFrontiers in toxicology · 2024
    Review
  6. Article
  7. Identifying xenobiotic metabolites withFrontiers in toxicology · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Adam M SpeenOak Ridge Institute for Science and Education (ORISE), Oak Ridge, Tennessee 37830, USA.ORCID 0000-0002-3153-8378
Jessica R MurrayCPHEA, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.
Quentin Todd KrantzCPHEA, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.
David DaviesCPHEA, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.
Paul EvanskyCPHEA, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.
Joshua A HarrillCCTE, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.ORCID 0000-0003-4317-6391
Logan J EverettCCTE, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.ORCID 0000-0002-9713-6099
Joseph L BundyCCTE, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.
Lisa A DaileyCPHEA, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.
Jazzlyn HillCPHEA, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.
Wyatt ZanderCPHEA, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.
Elise CarlstenCPHEA, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.
Michael MonseesCPHEA, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.
Jose ZavalaMedTec BioLab Inc., Hillsborough, North Carolina 27278, USA.ORCID 0000-0001-8286-6577
Mark A HiguchiCPHEA, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27709, USA.ORCID 0000-0001-6202-2369
Environmental Protection Agency · USOak Ridge Associated Universities · US

Funding

EPAIntramural EPA EPA999999
6 · The paper itself

Abstract

Inhalation is the most relevant route of volatile organic chemical (VOC) exposure; however, due to unique challenges posed by their chemical properties and poor solubility in aqueous solutions, in vitro chemical safety testing is predominantly performed using direct application dosing/submerged exposures. To address the difficulties in screening toxic effects of VOCs, our cell culture exposure system permits cells to be exposed to multiple concentrations at air-liquid interface (ALI) in a 24-well format. ALI exposure methods permit direct chemical-to-cell interaction with the test article at physiological conditions. In the present study, BEAS-2B and primary normal human bronchial epithelial cells (pHBEC) are used to assess gene expression, cytotoxicity, and cell viability responses to a variety of volatile chemicals including acrolein, formaldehyde, 1,3-butadiene, acetaldehyde, 1-bromopropane, carbon tetrachloride, dichloromethane, and trichloroethylene. BEAS-2B cells were exposed to all the test agents, whereas pHBECs were only exposed to the latter 4 listed above. The VOC concentrations tested elicited only slight cell viability changes in both cell types. Gene expression changes were analyzed using benchmark dose (BMD) modeling. The BMD for the most sensitive gene set was within one order of magnitude of the threshold-limit value reported by the American Conference of Governmental Industrial Hygienists, and the most sensitive gene sets impacted by exposure correlate to known adverse health effects recorded in epidemiologic and in vivo exposure studies. Overall, our study outlines a novel in vitro approach for evaluating molecular-based points-of-departure in human airway epithelial cell exposure to volatile chemicals.

Indexed as

Air PollutantsVolatile Organic CompoundsAcetaldehydeBenchmarkingFormaldehydeHumansAcetaldehydeAir PollutantsFormaldehydeVolatile Organic Compoundsbenchmark dosecell culture exposure systeminhalationin vitrotranscriptomicsVOC

Identifiers

PMID35426944
PMCPMC9704371
OpenAlexW4223934747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.